175 related articles for article (PubMed ID: 19458766)
1. A mathematical model for the onset of avascular tumor growth in response to the loss of p53 function.
Levine HA; Smiley MW; Tucker AL; Nilsen-Hamilton M
Cancer Inform; 2007 Feb; 2():163-88. PubMed ID: 19458766
[TBL] [Abstract][Full Text] [Related]
2. The role of cooperativity in a p53-miR34 dynamical mathematical model.
Nikolov S; Wolkenhauer O; Vera J; Nenov M
J Theor Biol; 2020 Jun; 495():110252. PubMed ID: 32199858
[TBL] [Abstract][Full Text] [Related]
3. Estimating the selective advantage of mutant p53 tumour cells to repeated rounds of hypoxia.
Gammack D; Byrne HM; Lewis CE
Bull Math Biol; 2001 Jan; 63(1):135-66. PubMed ID: 11146880
[TBL] [Abstract][Full Text] [Related]
4. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.
Cadwell C; Zambetti GP
Gene; 2001 Oct; 277(1-2):15-30. PubMed ID: 11602342
[TBL] [Abstract][Full Text] [Related]
5. A kinetic view of acid-mediated tumor invasion.
Fouad AM
Eur Biophys J; 2018 Mar; 47(2):185-189. PubMed ID: 29374772
[TBL] [Abstract][Full Text] [Related]
6. Wild-type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells.
Toschi E; Rota R; Antonini A; Melillo G; Capogrossi MC
J Invest Dermatol; 2000 Jun; 114(6):1188-94. PubMed ID: 10844565
[TBL] [Abstract][Full Text] [Related]
7. Association of allelic imbalance at locus D13S171 (BRCA2) and p53 alterations with tumor kinetics and chromosomal instability (aneuploidy) in nonsmall cell lung carcinoma.
Gorgoulis VG; Kotsinas A; Zacharatos P; Mariatos G; Liloglou T; Tsoli E; Kokotas S; Fassoulas C; Field JK; Kittas C
Cancer; 2000 Nov; 89(9):1933-45. PubMed ID: 11064350
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
[TBL] [Abstract][Full Text] [Related]
9. The effect of time delays on the dynamics of avascular tumor growth.
Byrne HM
Math Biosci; 1997 Sep; 144(2):83-117. PubMed ID: 9258002
[TBL] [Abstract][Full Text] [Related]
10. Differential equations with applications in cancer diseases.
Ilea M; Turnea M; Rotariu M
Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):572-7. PubMed ID: 24340548
[TBL] [Abstract][Full Text] [Related]
11. Some implications of Scale Relativity theory in avascular stages of growth of solid tumors in the presence of an immune system response.
Buzea CG; Agop M; Moraru E; Stana BA; Gîrţu M; Iancu D
J Theor Biol; 2011 Aug; 282(1):52-64. PubMed ID: 21600219
[TBL] [Abstract][Full Text] [Related]
12. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
13. The gene encoding p202, an interferon-inducible negative regulator of the p53 tumor suppressor, is a target of p53-mediated transcriptional repression.
D'Souza S; Xin H; Walter S; Choubey D
J Biol Chem; 2001 Jan; 276(1):298-305. PubMed ID: 11013253
[TBL] [Abstract][Full Text] [Related]
14. Posttranslational regulation of p53 tumor suppressor protein function.
Maxwell SA; Roth JA
Crit Rev Oncog; 1994; 5(1):23-57. PubMed ID: 7948107
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53.
Loging WT; Reisman D
Oncogene; 1999 Dec; 18(52):7608-15. PubMed ID: 10602522
[TBL] [Abstract][Full Text] [Related]
16. Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target.
Wu Q; Ding W; Mirza A; Van Arsdale T; Wei I; Bishop WR; Basso A; McClanahan T; Luo L; Kirschmeier P; Gustafson E; Hernandez M; Liu S
J Biol Chem; 2005 Apr; 280(13):12935-43. PubMed ID: 15659406
[TBL] [Abstract][Full Text] [Related]
17. Andrographolide induces degradation of mutant p53 via activation of Hsp70.
Sato H; Hiraki M; Namba T; Egawa N; Baba K; Tanaka T; Noshiro H
Int J Oncol; 2018 Aug; 53(2):761-770. PubMed ID: 29845212
[TBL] [Abstract][Full Text] [Related]
18. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.
Kalo E; Buganim Y; Shapira KE; Besserglick H; Goldfinger N; Weisz L; Stambolsky P; Henis YI; Rotter V
Mol Cell Biol; 2007 Dec; 27(23):8228-42. PubMed ID: 17875924
[TBL] [Abstract][Full Text] [Related]
20. p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies.
Moll UM; Ostermeyer AG; Ahomadegbe JC; Mathieu MC; Riou G
Hum Pathol; 1995 Dec; 26(12):1293-301. PubMed ID: 8522300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
